170 related articles for article (PubMed ID: 19223692)
1. Nigral degeneration with inclusion body formation and behavioral changes in rats after proteasomal inhibition.
Niu C; Mei J; Pan Q; Fu X
Stereotact Funct Neurosurg; 2009; 87(2):69-81. PubMed ID: 19223692
[TBL] [Abstract][Full Text] [Related]
2. α-Synuclein fibril-induced inclusion spread in rats and mice correlates with dopaminergic Neurodegeneration.
Abdelmotilib H; Maltbie T; Delic V; Liu Z; Hu X; Fraser KB; Moehle MS; Stoyka L; Anabtawi N; Krendelchtchikova V; Volpicelli-Daley LA; West A
Neurobiol Dis; 2017 Sep; 105():84-98. PubMed ID: 28576704
[TBL] [Abstract][Full Text] [Related]
3. Retrograde dopaminergic neuron degeneration following intrastriatal proteasome inhibition.
Miwa H; Kubo T; Suzuki A; Nishi K; Kondo T
Neurosci Lett; 2005 May 20-27; 380(1-2):93-8. PubMed ID: 15854758
[TBL] [Abstract][Full Text] [Related]
4. Nigral injection of a proteasomal inhibitor, lactacystin, induces widespread glial cell activation and shows various phenotypes of Parkinson's disease in young and adult mouse.
Savolainen MH; Albert K; Airavaara M; Myöhänen TT
Exp Brain Res; 2017 Jul; 235(7):2189-2202. PubMed ID: 28439627
[TBL] [Abstract][Full Text] [Related]
5. Proteasome inhibition causes nigral degeneration with inclusion bodies in rats.
McNaught KS; Björklund LM; Belizaire R; Isacson O; Jenner P; Olanow CW
Neuroreport; 2002 Aug; 13(11):1437-41. PubMed ID: 12167769
[TBL] [Abstract][Full Text] [Related]
6. Reproducible nigral cell loss after systemic proteasomal inhibitor administration to rats.
Zeng BY; Bukhatwa S; Hikima A; Rose S; Jenner P
Ann Neurol; 2006 Aug; 60(2):248-52. PubMed ID: 16862581
[TBL] [Abstract][Full Text] [Related]
7. Fine structure and biochemical mechanisms underlying nigrostriatal inclusions and cell death after proteasome inhibition.
Fornai F; Lenzi P; Gesi M; Ferrucci M; Lazzeri G; Busceti CL; Ruffoli R; Soldani P; Ruggieri S; Alessandri MG; Paparelli A
J Neurosci; 2003 Oct; 23(26):8955-66. PubMed ID: 14523098
[TBL] [Abstract][Full Text] [Related]
8. G2019S LRRK2 and aging confer susceptibility to proteasome inhibitor-induced neurotoxicity in nigrostriatal dopaminergic system.
Xiao Q; Yang S; Le W
J Neural Transm (Vienna); 2015 Dec; 122(12):1645-57. PubMed ID: 26253900
[TBL] [Abstract][Full Text] [Related]
9. [Sleep changes during degeneration of neurons in the substantia nigra induced by inhibitor of proteasomes lactacystin in rats].
Pastukhov IuF; Chesnokova AIu; Iakimchuk AA; Ekimova IV; Romanova IV; Khudik KA
Ross Fiziol Zh Im I M Sechenova; 2010 Dec; 96(12):1190-202. PubMed ID: 21473106
[TBL] [Abstract][Full Text] [Related]
10. Parkinson-like neurodegeneration induced by targeted overexpression of alpha-synuclein in the nigrostriatal system.
Kirik D; Rosenblad C; Burger C; Lundberg C; Johansen TE; Muzyczka N; Mandel RJ; Björklund A
J Neurosci; 2002 Apr; 22(7):2780-91. PubMed ID: 11923443
[TBL] [Abstract][Full Text] [Related]
11. Reduced TH expression and α-synuclein accumulation contribute towards nigrostriatal dysfunction in experimental hepatic encephalopathy.
Suárez I; Bodega G; Rubio M; Fernández B
Restor Neurol Neurosci; 2017; 35(5):469-481. PubMed ID: 28984618
[TBL] [Abstract][Full Text] [Related]
12. Non-invasive evaluation of nigrostriatal neuropathology in a proteasome inhibitor rodent model of Parkinson's disease.
Vernon AC; Johansson SM; Modo MM
BMC Neurosci; 2010 Jan; 11():1. PubMed ID: 20051106
[TBL] [Abstract][Full Text] [Related]
13. AAV1/2-induced overexpression of A53T-α-synuclein in the substantia nigra results in degeneration of the nigrostriatal system with Lewy-like pathology and motor impairment: a new mouse model for Parkinson's disease.
Ip CW; Klaus LC; Karikari AA; Visanji NP; Brotchie JM; Lang AE; Volkmann J; Koprich JB
Acta Neuropathol Commun; 2017 Feb; 5(1):11. PubMed ID: 28143577
[TBL] [Abstract][Full Text] [Related]
14. Time course and magnitude of alpha-synuclein inclusion formation and nigrostriatal degeneration in the rat model of synucleinopathy triggered by intrastriatal α-synuclein preformed fibrils.
Patterson JR; Duffy MF; Kemp CJ; Howe JW; Collier TJ; Stoll AC; Miller KM; Patel P; Levine N; Moore DJ; Luk KC; Fleming SM; Kanaan NM; Paumier KL; El-Agnaf OMA; Sortwell CE
Neurobiol Dis; 2019 Oct; 130():104525. PubMed ID: 31276792
[TBL] [Abstract][Full Text] [Related]
15. Intrastriatal injection of pre-formed mouse α-synuclein fibrils into rats triggers α-synuclein pathology and bilateral nigrostriatal degeneration.
Paumier KL; Luk KC; Manfredsson FP; Kanaan NM; Lipton JW; Collier TJ; Steece-Collier K; Kemp CJ; Celano S; Schulz E; Sandoval IM; Fleming S; Dirr E; Polinski NK; Trojanowski JQ; Lee VM; Sortwell CE
Neurobiol Dis; 2015 Oct; 82():185-199. PubMed ID: 26093169
[TBL] [Abstract][Full Text] [Related]
16. Proteasome inhibitors protect against degeneration of nigral dopaminergic neurons in hemiparkinsonian rats.
Inden M; Kondo J; Kitamura Y; Takata K; Nishimura K; Taniguchi T; Sawada H; Shimohama S
J Pharmacol Sci; 2005 Feb; 97(2):203-11. PubMed ID: 15684568
[TBL] [Abstract][Full Text] [Related]
17. c-Jun N-terminal kinase mediates lactacystin-induced dopamine neuron degeneration.
Li X; Du Y; Fan X; Yang D; Luo G; Le W
J Neuropathol Exp Neurol; 2008 Oct; 67(10):933-44. PubMed ID: 18800014
[TBL] [Abstract][Full Text] [Related]
18. Alterations in lysosomal and proteasomal markers in Parkinson's disease: relationship to alpha-synuclein inclusions.
Chu Y; Dodiya H; Aebischer P; Olanow CW; Kordower JH
Neurobiol Dis; 2009 Sep; 35(3):385-98. PubMed ID: 19505575
[TBL] [Abstract][Full Text] [Related]
19. Lewy body-like alpha-synuclein inclusions trigger reactive microgliosis prior to nigral degeneration.
Duffy MF; Collier TJ; Patterson JR; Kemp CJ; Luk KC; Tansey MG; Paumier KL; Kanaan NM; Fischer DL; Polinski NK; Barth OL; Howe JW; Vaikath NN; Majbour NK; El-Agnaf OMA; Sortwell CE
J Neuroinflammation; 2018 May; 15(1):129. PubMed ID: 29716614
[TBL] [Abstract][Full Text] [Related]
20. Proteasomal inhibition causes loss of nigral tyrosine hydroxylase neurons.
Schapira AH; Cleeter MW; Muddle JR; Workman JM; Cooper JM; King RH
Ann Neurol; 2006 Aug; 60(2):253-5. PubMed ID: 16862591
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
